S&P 500   3,953.31 (+0.49%)
DOW   33,764.04 (+0.49%)
QQQ   283.57 (+1.08%)
AAPL   142.61 (+1.18%)
MSFT   246.85 (+1.01%)
META   115.12 (+1.04%)
GOOGL   93.63 (-1.38%)
AMZN   89.78 (+1.49%)
TSLA   171.19 (-1.64%)
NVDA   167.77 (+4.08%)
NIO   13.21 (+5.01%)
BABA   92.99 (+5.28%)
AMD   70.45 (+0.44%)
T   19.25 (-0.26%)
MU   55.37 (+2.88%)
CGC   3.16 (-2.47%)
F   13.18 (+0.61%)
GE   84.42 (-0.68%)
DIS   92.51 (+0.39%)
AMC   6.22 (+2.81%)
PYPL   75.29 (+1.17%)
PFE   50.79 (+1.09%)
NFLX   308.59 (+0.06%)
S&P 500   3,953.31 (+0.49%)
DOW   33,764.04 (+0.49%)
QQQ   283.57 (+1.08%)
AAPL   142.61 (+1.18%)
MSFT   246.85 (+1.01%)
META   115.12 (+1.04%)
GOOGL   93.63 (-1.38%)
AMZN   89.78 (+1.49%)
TSLA   171.19 (-1.64%)
NVDA   167.77 (+4.08%)
NIO   13.21 (+5.01%)
BABA   92.99 (+5.28%)
AMD   70.45 (+0.44%)
T   19.25 (-0.26%)
MU   55.37 (+2.88%)
CGC   3.16 (-2.47%)
F   13.18 (+0.61%)
GE   84.42 (-0.68%)
DIS   92.51 (+0.39%)
AMC   6.22 (+2.81%)
PYPL   75.29 (+1.17%)
PFE   50.79 (+1.09%)
NFLX   308.59 (+0.06%)
S&P 500   3,953.31 (+0.49%)
DOW   33,764.04 (+0.49%)
QQQ   283.57 (+1.08%)
AAPL   142.61 (+1.18%)
MSFT   246.85 (+1.01%)
META   115.12 (+1.04%)
GOOGL   93.63 (-1.38%)
AMZN   89.78 (+1.49%)
TSLA   171.19 (-1.64%)
NVDA   167.77 (+4.08%)
NIO   13.21 (+5.01%)
BABA   92.99 (+5.28%)
AMD   70.45 (+0.44%)
T   19.25 (-0.26%)
MU   55.37 (+2.88%)
CGC   3.16 (-2.47%)
F   13.18 (+0.61%)
GE   84.42 (-0.68%)
DIS   92.51 (+0.39%)
AMC   6.22 (+2.81%)
PYPL   75.29 (+1.17%)
PFE   50.79 (+1.09%)
NFLX   308.59 (+0.06%)
S&P 500   3,953.31 (+0.49%)
DOW   33,764.04 (+0.49%)
QQQ   283.57 (+1.08%)
AAPL   142.61 (+1.18%)
MSFT   246.85 (+1.01%)
META   115.12 (+1.04%)
GOOGL   93.63 (-1.38%)
AMZN   89.78 (+1.49%)
TSLA   171.19 (-1.64%)
NVDA   167.77 (+4.08%)
NIO   13.21 (+5.01%)
BABA   92.99 (+5.28%)
AMD   70.45 (+0.44%)
T   19.25 (-0.26%)
MU   55.37 (+2.88%)
CGC   3.16 (-2.47%)
F   13.18 (+0.61%)
GE   84.42 (-0.68%)
DIS   92.51 (+0.39%)
AMC   6.22 (+2.81%)
PYPL   75.29 (+1.17%)
PFE   50.79 (+1.09%)
NFLX   308.59 (+0.06%)
NASDAQ:CGIX

Cancer Genetics - CGIX Stock Forecast, Price & News

$1.01
-0.27 (-21.09%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.00
$1.37
50-Day Range
$0.38
$4.61
52-Week Range
$2.11
$17.50
Volume
53,658 shs
Average Volume
2.44 million shs
Market Capitalization
$4.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CGIX stock logo

About Cancer Genetics (NASDAQ:CGIX) Stock

Vyant Bio, Inc. is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities. It leveraging these modalities, the company is able to capitalize on repurposed and novel compounds and then partner with others to further develop and commercialize valuable therapeutics and new treatments for patients. It operates two wholly-owned subsidiaries, StemoniX and vivoPharm. Vyant Bio was founded in 1999 and is headquartered in Cherry Hill, NJ.

Receive CGIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter.

CGIX Stock News Headlines

See More Headlines
Receive CGIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CGIX
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$4.13 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • John A. Roberts
    President, Chief Executive Officer & Director
  • Andrew D. C. LaFrence
    Chief Operating & Financial Officer
  • Robert T. Fremeau
    Chief Scientific Officer
  • Ping Yeh
    Director & Chief Innovation Officer
  • Ralf Brandt
    President-Discovery & Early Development Services













CGIX Stock - Frequently Asked Questions

How have CGIX shares performed in 2022?

Cancer Genetics' stock was trading at $1.12 at the start of the year. Since then, CGIX stock has decreased by 9.8% and is now trading at $1.01.
View the best growth stocks for 2022 here
.

What is Panna Sharma's approval rating as Cancer Genetics' CEO?

28 employees have rated Cancer Genetics Chief Executive Officer Panna Sharma on Glassdoor.com. Panna Sharma has an approval rating of 37% among the company's employees. This puts Panna Sharma in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cancer Genetics own?
What is Cancer Genetics' stock symbol?

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How do I buy shares of Cancer Genetics?

Shares of CGIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cancer Genetics' stock price today?

One share of CGIX stock can currently be purchased for approximately $1.01.

How much money does Cancer Genetics make?

Cancer Genetics (NASDAQ:CGIX) has a market capitalization of $4.13 million.

How can I contact Cancer Genetics?

Cancer Genetics' mailing address is 201 State Rt 17 Fl 2, Rutherford, New Jersey 07070-2597. The official website for the company is www.cancergenetics.com. The company can be reached via phone at (201) 479-1357.

This page (NASDAQ:CGIX) was last updated on 12/8/2022 by MarketBeat.com Staff